Scholarlink

Background <p>Using large data to propose new uses of drugs has potential to rapidly prioritize new treatments for major diseases of public health importance. One comprehensive data set, LINCS L1000 Connectivity Map, profiles gene expression associated with thousands of compounds, including many with known clinical uses. But, some recent studies have questioned the reliability of this data, and the best approach to use this resource for drug repositioning is not well established.</p> Methods <p>Here, we develop a novel generalizable approach by hypothesizing that new treatments for a disease should induce similar gene expression to existing treatments for a disease. Using the Drug Repurposing Hub compendium of known treatments, we formulate a combined logistic regression model to predict new drug indications, and we assess generalizability of our findings using independent clinical trials on experimental drug uses.</p> Results <p>We support the hypothesis that drugs sharing an indication induce more similar gene expression, additionally demonstrating that the simpler Spearman correlation (<i>p</i> = 7.71e-38), outperforms the popular Connectivity Score (<i>p</i> = 5.2e-6). Our final model, combining predicted drug indications across three diverse cell lines, generalizes to predict experimental clinical trials with AUC of 0.708.</p> Conclusions <p>By developing a new approach to using LINCS L1000 data for drug repositioning, we both propose plausible new disease treatments and provide an interpretable rationale for predictions. Our findings not only put forward new drug repositioning candidates, browseable at <a href="https://bsultan.shinyapps.io/web-app">https://bsultan.shinyapps.io/web-app</a>, but they also provide guidelines for future researchers employing L1000 data for drug repurposing.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Exploiting similarity in drug molecular effects for drug repurposing

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月30日

查看全文
  • Katie Huang,
  • Panagiotis Nikolaos Lalagkas,
  • Beftu Sultan,
  • Rachel Melamed

摘要

Background

Using large data to propose new uses of drugs has potential to rapidly prioritize new treatments for major diseases of public health importance. One comprehensive data set, LINCS L1000 Connectivity Map, profiles gene expression associated with thousands of compounds, including many with known clinical uses. But, some recent studies have questioned the reliability of this data, and the best approach to use this resource for drug repositioning is not well established.

Methods

Here, we develop a novel generalizable approach by hypothesizing that new treatments for a disease should induce similar gene expression to existing treatments for a disease. Using the Drug Repurposing Hub compendium of known treatments, we formulate a combined logistic regression model to predict new drug indications, and we assess generalizability of our findings using independent clinical trials on experimental drug uses.

Results

We support the hypothesis that drugs sharing an indication induce more similar gene expression, additionally demonstrating that the simpler Spearman correlation (p = 7.71e-38), outperforms the popular Connectivity Score (p = 5.2e-6). Our final model, combining predicted drug indications across three diverse cell lines, generalizes to predict experimental clinical trials with AUC of 0.708.

Conclusions

By developing a new approach to using LINCS L1000 data for drug repositioning, we both propose plausible new disease treatments and provide an interpretable rationale for predictions. Our findings not only put forward new drug repositioning candidates, browseable at https://bsultan.shinyapps.io/web-app, but they also provide guidelines for future researchers employing L1000 data for drug repurposing.